The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.

MLA

Tucker, Thomas J., et al. “The Design and Synthesis of Diaryl Ether Second Generation HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) with Enhanced Potency versus Key Clinical Mutations.” Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 9, May 2008, pp. 2959–66. EBSCOhost, https://doi.org/10.1016/j.bmcl.2008.03.064.

APA

Tucker, T. J., Saggar, S., Sisko, J. T., Tynebor, R. M., Williams, T. M., Felock, P. J., Flynn, J. A., Lai, M.-T., Liang, Y., McGaughey, G., Liu, M., Miller, M., Moyer, G., Munshi, V., Perlow-Poehnelt, R., Prasad, S., Sanchez, R., Torrent, M., Vacca, J. P., … Yan, Y. (2008). The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations. Bioorganic & Medicinal Chemistry Letters, 18(9), 2959–2966. https://doi.org/10.1016/j.bmcl.2008.03.064

Chicago

Tucker, Thomas J, Sandeep Saggar, John T Sisko, Robert M Tynebor, Theresa M Williams, Peter J Felock, Jessica A Flynn, et al. 2008. “The Design and Synthesis of Diaryl Ether Second Generation HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) with Enhanced Potency versus Key Clinical Mutations.” Bioorganic & Medicinal Chemistry Letters 18 (9): 2959–66. doi:10.1016/j.bmcl.2008.03.064.